Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.

被引：0
|
作者：
Al-Rajabi, Raed Moh'd Taiseer
Kasi, Anup
Baranda, Joaquina Celebre
Saeed, Anwaar
Li, Haoran
Bruey, Collin
Best, Shaun
Phadnis, Milind A.
Sun, Weijing
机构：
[1] Univ Kansas, Canc Ctr, Westwood, KS USA
[2] Univ Kansas, Canc Ctr, Fairway, KS USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Univ Kansas, Med Ctr, Kansas City, KS USA
[5] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-237-2581-144; 261-492-3532-2370-7650-2700; 613-225-313; 298-145-222-184-1022-9122; 261-492-2769; 281-5277-2560; 283-2494; 7; 4; 3; 2; 250; 2018; 91; 176; 62; 6; 1; 38092-18909; 38116-38094-8; 5;
D O I：
10.1200/JCO.2024.42.3_suppl.TPS581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS581
引用
收藏
页码：TPS581 / TPS581
页数：1
相关论文
共 50 条
  • [1] A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Sarfaty, Michal
    Ostrovnaya, Irina
    Teo, Min Yuen
    Iyer, Gopa
    Lee, Chung-Han
    Peters, Vanessa
    Durocher, Jennifer
    Regazzi, Ashley Marie
    Mccoy, Asia S.
    Hettich, Grace
    Al-Ahmadie, Hikmat
    Chaim, Joshua
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    Funt, Samuel Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] A Phase 2 Trial of Regorafenib as a Single Agent in Patients With Chemotherapy-Refractory, Advanced, and Metastatic Biliary Tract Adenocarcinoma
    Sun, Weijing
    Patel, Anuj
    Normolle, Daniel
    Patel, Krishna
    Ohr, James
    Lee, James J.
    Bahary, Nathan
    Chu, Edward
    Streeter, Natalie
    Drummond, Summer
    CANCER, 2019, 125 (06) : 902 - 909
  • [3] Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
    Kim, Richard D.
    Poklepovic, Andrew Stewart
    Nixon, Andrew B.
    Kim, Dae Won
    Soares, Heloisa P.
    Kim, Jongphil
    Zhou, Jun Min
    Tariq, Fatima
    Burgess, Natalie
    Sanoff, Hanna Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours
    Domchek, S.
    Bang, Y-J
    Coukos, G.
    Kobayashi, K.
    Baker, N.
    McMurtry, E.
    Song, W.
    Kaufman, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
    Shiraishi, Yoshimasa
    Shimose, Takayuki
    Tsuchiya-Kawano, Yuko
    Ishii, Hidenobu
    Daga, Haruko
    Ito, Kentaro
    Saruwatari, Koichi
    Okamoto, Isamu
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3449 - 3453
  • [6] Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
    Soares, Heloisa P.
    Kothari, Nishi
    Mahipal, Amit
    Springett, Gregory M.
    Kim, Jongphil
    Tariq, Fatima
    Sanoff, Hanna Kelly
    Poklepovic, Andrew Stewart
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors
    Gonzalez-Cao, M.
    Martinez-Picado, J.
    Provencio Pulla, M.
    Clotet, B.
    Juan, O.
    Dalmau, J.
    Moran, T.
    Mayerhans, A.
    De Castro, J.
    Blanco, J.
    Blanco, R.
    Bernabe Caro, R.
    Karachaliou, N.
    Garcia-Corbacho, J.
    Molina, M. A.
    Brander, C.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.
    Andemicael, Luchia
    Chang, Hewitt
    Anwar, Moshiur Mekhail
    Bauer, Kelly
    Gordan, John
    Johnson, Jamese
    Keenan, Bridget P.
    Venook, Alan P.
    Wang, Chia-Ching Jackie
    Zhang, Karen
    Fong, Lawrence
    Kelley, Robin Kate
    Feng, Mary Uan-Sian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS630 - TPS630
  • [9] A PHASE I TRIAL OF TREMELIMUMAB, DURVALUMAB (MEDI4736) AND BELINOSTAT IN ARID1A MUTATED CANCERS WITH FOCUS ON UROTHELIAL CARCINOMA (RESOLVE)
    Gupta, Sumati
    Maughan, Benjamin
    Kohli, Manish
    Cairns, Bradley
    Swami, Umang
    Agarwal, Neeraj
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A694 - A694
  • [10] Ibrutinib plus durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
    Borazanci, Erkut Hasan
    Hong, David S.
    Gutierrez, Martin
    Rasco, Drew W.
    Reid, Tony R.
    Veeder, Michael H.
    Tawashi, Ahmed
    Lin, Jennifer
    Dimery, Isaiah W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345